2019
DOI: 10.1016/j.trim.2019.01.002
|View full text |Cite
|
Sign up to set email alerts
|

Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
12
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 17 publications
(14 citation statements)
references
References 52 publications
2
12
0
Order By: Relevance
“…41 Moreover, our previous study in a chronic renal allograft dysfunction model demonstrated that PPAR-γ agonists inhibit NF-κB activation and infiltration of inflammatory cells into the interstitium. 42 In the present study, we showed that activation of PPAR-γ with RGTZ inhibits NF-κB activation, macrophage infiltration, and reduces expression of MCP-1, RANTES, TNF-α, and IL-1β induced by hyperuricemia. These data suggest that inhibition of the inflammatory response may be another mechanism by which RGTZ attenuates the renal fibrosis and the development of HN.…”
Section: Discussionsupporting
confidence: 54%
“…41 Moreover, our previous study in a chronic renal allograft dysfunction model demonstrated that PPAR-γ agonists inhibit NF-κB activation and infiltration of inflammatory cells into the interstitium. 42 In the present study, we showed that activation of PPAR-γ with RGTZ inhibits NF-κB activation, macrophage infiltration, and reduces expression of MCP-1, RANTES, TNF-α, and IL-1β induced by hyperuricemia. These data suggest that inhibition of the inflammatory response may be another mechanism by which RGTZ attenuates the renal fibrosis and the development of HN.…”
Section: Discussionsupporting
confidence: 54%
“…Hippo signaling was predicted to be decreased and Rho signaling was predicted to be increased in the SAGN tubulointerstitium, possibly predisposing to interstitial fibrosis 36 38 . In addition, the SAGN interstitium also showed lack of activation of pathways that could potentially protect against the development of chronic kidney damage, such as PPARα, LXR-RXR and eNOS signaling 39 , 40 . The latter were more prominently expressed in IgAN in our study as well in a study by Liu et al 41 .…”
Section: Discussionmentioning
confidence: 99%
“…PPAR‐γ is expressed in different parts of nephron involving glomerulus, proximal tubules, and collecting ducts, which suggests its role in renal patho‐physiology (Singh, Singh, & Bhatti, 2014). PPAR‐γ agonists have been used as insulin sensitizing agents in the management of type‐2 diabetes mellitus and have been documented to attenuate AKI, which is attributed to their anti‐oxidant, anti‐apoptotic, and anti‐inflammatory activity in nondiabetic models (Cai et al, 2018; Chandra, Miriyala, & Panchatcharam, 2017; Deng et al, 2019; Singh et al, 2016). Ciglitazone, a PPAR‐γ agonist, decreased the free radical generation and angiotensin‐II as well as thromboxane‐A 2 mediated renal vasoconstriction in glycerol‐induced AKI (Yousefipour, Hercule, Truong, Oyekan, & Newaz, 2007).…”
Section: Discussionmentioning
confidence: 99%